

POLICY NAME	Increlex (mecasermin)	POLICY #	1231P
--------------------	-----------------------	-----------------	-------

Criteria

Criteria for Treatment of Primary Insulin-Like Growth Factor-1 Deficiency

- ☐ Prescribed by a specialist familiar with the diagnosis and treatment of primary insulin-like growth factor-

deficiency

- ☐ Age 2 years or older
- ☐ Basal insulin-like growth factor-1 standard deviation score -3 for age and sex
- ☐ Height standard deviation score -3 for age and sex
- ☐ Normal or near normal growth hormone levels (> 10 ng/dL following stimulation, or basal level > 5 ng/dL)
- ☐ Approval Time: 12 months
- ☐ Renewal requires documentation of:
 - Growth velocity 2 cm per year and epiphyses are open

Criteria for Treatment of Growth Failure in Children with Growth Hormone Gene Deletion who have Developed Neutralizing Antibodies to Growth Hormone

- ☐ Prescribed by a specialist familiar with the diagnosis and treatment of growth hormone deficiencies
- ☐ Age 2 years or older
- ☐ Diagnosis of growth hormone gene deletion who have developed neutralizing antibodies to growth hormone
- ☐ Approval Time: 12 months
- ☐ Renewal requires documentation of:
 - Growth velocity 2 cm per year and epiphyses are open

Exclusion Criteria – Any of the following prevents coverage

- ☐ Idiopathic Short Stature (ISS)

- ☐ Idiopathic short stature is considered a clinical description and not a diagnosis of an illness, injury or disease. Due to this, coverage of mecasermin for the treatment of idiopathic short stature (ISS) is not considered medically necessary. References

- ☐ ISS is generally considered a normal variant of growth
 - Long-term benefits of intervention are unclear
 - Predictions of adult height, with or without treatment, are imprecise

- ☐ Most patients with ISS have normal psychosocial functioning
 - Short stature could not be established as the cause of problems with peer relationships
 - The effects have not been adequately studied
 - Short stature has a minimal impact on peer perceptions of social behavior, friendship, or peer acceptance HCPCS Codes J2170 Injection, mecasermin, 1 mg